Nasdaq:US$9.56 (+0.50) | HKEX:HK$15.34 (+0.18) | AIM:£1.50 (+0.01)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.